Patrick Timms, MD
Rheumatology · Pueblo, CONPI 1861455099
Payments from drug & device makers
Across 999 payments — averaging $14.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Amgen$3K
- Novartis$1K
- AstraZeneca$968
- Johnson & Johnson$964
- Pfizer$746
- plus $4K from 28 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 320 | $4,417 |
| Amgen(2 entities) | 249 | $3,132 |
| Novartis | 75 | $1,029 |
| AstraZeneca(2 entities) | 47 | $968 |
| Johnson & Johnson | 46 | $964 |
| Pfizer | 61 | $746 |
| UCB, Inc. | 38 | $671 |
| GSK | 26 | $459 |
| Lilly USA, LLC | 19 | $378 |
| E.r. Squibb & Sons, L.L.C. | 16 | $301 |
| Sanofi | 18 | $273 |
| Boehringer Ingelheim | 8 | $233 |
| Genentech USA, Inc. | 13 | $182 |
| Bristol Myers Squibb | 15 | $165 |
| Sandoz | 6 | $157 |
| Regeneron Healthcare Solutions, Inc. | 8 | $123 |
| Fresenius Kabi USA, LLC | 4 | $85 |
| Radius Health, Inc. | 4 | $76 |
| Sanofi-aventis U.S. LLC | 2 | $59 |
| Eisai Inc. | 3 | $56 |
| ANI Pharmaceuticals, Inc. | 2 | $53 |
| Genentech, Inc. | 1 | $50 |
| Hikma Pharmaceuticals USA | 3 | $44 |
| Mylan Institutional Inc. | 2 | $43 |
| Aurinia Pharma U.S., Inc. | 2 | $36 |
| Bioventus LLC | 2 | $33 |
| Sebela Pharmaceuticals Inc. | 2 | $28 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Pacira Therapeutics, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| Merck | 1 | $14 |
| Dynasplint Systems Inc. | 1 | $13 |
How this compares
$14,878 in reported general payments places this provider in the 70th percentile of 108 rheumatology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Pueblo
- Rupal ChavdaPueblo$2K
- Michael ThakorFort Collins$7.3M
- Christopher AntoliniDenver$6.9M
- Christopher StriebichAurora$2M
- Larry MorelandAurora$1.8M
- Kevin DeaneAurora$1.4M
- Mary DemoruelleDenver$1.2M
- Melissa GriffithAurora$667K
- Susan ChildressEnglewood$354K
- Vernon HolersAurora$315K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.